title: LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
abstract: We set out to generate new human myeloma tumors that grow in immunodeficient mice and can be used for pathophysiological studies and rapid evaluation of new therapies. Fresh whole core bone marrow (BM) biopsies taken from 33 myeloma patients were engrafted into the hind limb muscle of severe combined immunodeficient (SCID) mice. Human Ig was detected in 28/33 mice and three grew palpable tumors displaying many features of human myeloma including morphology, immunophenotype and BM plasmacytosis. Following intramuscular passage, we generated large numbers of mice with predictable increases in tumor growth and human paraprotein levels. We further characterized the model generated from an IgGlambda-producing tumor known as LAGlambda-1 and determined the effects of the proteasome inhibitor bortezomib, the alkylating agent melphalan, and the DNA damaging agent liposomal doxorubicin, on the growth of this tumor. LAGlambda-1-bearing mice receiving higher doses of bortezomib showed reduced tumor growth whereas a lower dose had no effect. In contrast, melphalan did not significantly alter tumor growth, except minimally at high doses, reflecting the resistance of this patient's tumor to this drug. We also used our intramuscular (i.m.) LAGlambda-1 model to optimize the dosing schedule of liposomal doxorubicin. Low doses administered once daily three days per week decreased tumor growth and human paraprotein levels whereas much higher doses given once weekly had no anti-myeloma effects. Furthermore, LAGlambda-1 cells produce local tumors when injected subcutaneously and lytic lesions when injected intravenously allowing for multiple methods of evaluating the anti-myeloma effects of a variety of agents. Our new clinically relevant SCID models of human myeloma should greatly facilitate drug development and enable novel therapies to quickly move from the laboratory to the clinic.
authors: Institute for Myeloma & Bone Cancer Research, West Hollywood, CA 90069, USA.
authors: Richard A
authors: RA
authors: Campbell
authors: Steven J
authors: SJ
authors: Manyak
authors: Honghao H
authors: HH
authors: Yang
authors: Nelida N
authors: NN
authors: Sjak-Shie
authors: Haiming
authors: H
authors: Chen
authors: Dorina
authors: D
authors: Gui
authors: Laura
authors: L
authors: Popoviciu
authors: Cathy
authors: C
authors: Wang
authors: Melinda
authors: M
authors: Gordon
authors: Shen
authors: S
authors: Pang
authors: Benjamin
authors: B
authors: Bonavida
authors: Jonathan
authors: J
authors: Said
authors: James R
authors: JR
authors: Berenson